Omranifard Victoria, Tarrahi Mohammad Javad, Sharifi Shima, Karahmadi Mojgan
Department of Psychiatry, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Biostatistics and Epidemiology, Faculty of Health, Lorestan University of Medical Sciences, Khorramabad, Iran.
Adv Biomed Res. 2018 Nov 28;7:148. doi: 10.4103/abr.abr_110_18. eCollection 2018.
This study aimed to evaluate the efficacy of memantine in the acute treatment of geriatric with bipolar disorder (BD) hospitalized for mania.
This study conducted on 70 patients older than 60 years with BD in the acute phase of mania. Oral sodium valproate was prescribed in both groups. The intervention group received memantine tablet and the placebo group received a placebo tablet based on a same procedure. Severity of mania, cognitive changes, and quality of life (QoL) were assessed and recorded 4 and 8 weeks after the beginning of the study. The collected data were analyzed with SPSS (version 20) using independent samples -test, analysis of variance in repeated observations, Chi-squared test, and Fisher's exact test.
Mania severity score had no significant difference at the beginning of the study, but 4 and 8 weeks after the intervention, it was reduced significantly in both groups ( < 0.001) that was higher in memantine group ( = 0.038). The mean increase in score of cognitive variations was 6.74 in the memantine group and 3.62 in the placebo group with a nonsignificant difference ( = 0.125). The scores of each dimension of QoL in the two groups showed that in all four dimensions, the patient's physical, psychological, social, and environmental status increased significantly by time ( < 0.001).
According to the results of this study, memantine as an adjuvant to administration of sodium valproate may have a significant effect on decreasing the intensity of mania in the long run.
本研究旨在评估美金刚在急性治疗因躁狂发作而住院的老年双相情感障碍(BD)患者中的疗效。
本研究针对70例60岁以上处于躁狂急性期的双相情感障碍患者开展。两组均开具丙戊酸钠口服药。干预组服用美金刚片,安慰剂组按相同程序服用安慰剂片。在研究开始后的4周和8周评估并记录躁狂严重程度、认知变化及生活质量(QoL)。收集的数据使用SPSS(版本20)进行分析,采用独立样本t检验、重复观测方差分析、卡方检验和Fisher精确检验。
研究开始时,两组躁狂严重程度评分无显著差异,但干预后4周和8周,两组评分均显著降低(P<0.001),美金刚组降低幅度更大(P = 0.038)。美金刚组认知变化评分的平均增加为6.74,安慰剂组为3.62,差异无统计学意义(P = 0.125)。两组生活质量各维度评分显示,在所有四个维度上,患者的身体、心理、社会和环境状况均随时间显著改善(P<0.001)。
根据本研究结果,美金刚作为丙戊酸钠给药的辅助药物,从长远来看可能对降低躁狂强度有显著效果。